Wedbush Adjusts Geron's Price Target to $7 From $6, Keeps Outperform Rating
Geron (GERN) has an average rating of outperform and price targets ranging from $4.50 to $10, according to analysts polled by Capital IQ. Price: 3.9886, Change: +0.04, Percent Change: +0.98
Geron Corp (GERN) Q1 2024 Earnings Call Transcript Highlights: Strategic Moves and Financial Health
Needham: Reiterates Geron (GERN.US) rating and adjusted from buy to buy rating, target price is $5.00.
Needham: Reiterates Geron (GERN.US) rating and adjusted from buy to buy rating, target price is $5.00.
Needham Reiterates Buy on Geron, Maintains $5 Price Target
Needham analyst Gil Blum reiterates Geron with a Buy and maintains $5 price target.
Buy Rating Affirmed for Geron Amid Positive Imetelstat Launch Prospects and Strong Financials
Geron (GERN.US): The 2024 Q1 financial report achieved revenue of US$304,000, with a previous value of US$21,000, with an expected value of US$20,000; earnings per share of -0.09 US dollars, previous value of -0.07 US dollars, and expected value of -0.10
Geron (GERN.US): The 2024 Q1 financial report achieved revenue of US$304,000, with a previous value of US$21,000, with an expected value of US$20,000; earnings per share of -0.09 US dollars, previous value of -0.07 US dollars, and expected value of -0.10 US dollars.
Geron Corporation Q1 Loss Increases, but Beats Estimates
Geron 1Q Rev $304,000 >GERN
Geron 1Q Rev $304,000 >GERN
As Of March 31, 2024, Geron Had Approximately $465M In Cash And Marketable Securities
As Of March 31, 2024, Geron Had Approximately $465M In Cash And Marketable Securities
Geron Q1 2024 GAAP EPS $(0.09) Beats $(0.10) Estimate, Sales $304.000K Beat $24.714K Estimate
Geron (NASDAQ:GERN) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.10) by 10 percent. This is a 28.57 percent decrease over losses of $(0.07) per share
Press Release: Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights
Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights June 16, 2024 PDUFA date for imetelstat NDA for the treatment of transfusion-dependent anemia in adult patients
Geron 1Q Loss/Shr 9c >GERN
Geron 1Q Loss/Shr 9c >GERN
Geron Cut to Neutral From Outperform by Baird
Geron Cut to Neutral From Outperform by Baird
Analysts Conflicted on These Healthcare Names: Dyne Therapeutics (DYN) and Geron (GERN)
Baird: Downgraded Geron (GERN.US) rating from being superior to the market to a neutral rating, with a target price of $4.50.
Baird: Downgraded Geron (GERN.US) rating from being superior to the market to a neutral rating, with a target price of $4.50.
Baird Downgrades Geron to Neutral, Maintains $4.5 Price Target
Baird analyst Joel Beatty downgrades Geron (NASDAQ:GERN) from Outperform to Neutral and maintains $4.5 price target.
TD Cowen Starts Geron at Buy, Cites Imetelstat Market Potential
Geron Initiated at Buy by TD Cowen
Geron Initiated at Buy by TD Cowen
Geron (GERN.US) was first covered by TD Cowen and was given a buy rating, with a target price of $10.00.
Geron (GERN.US) was first covered by TD Cowen and was given a buy rating, with a target price of $10.00.
TD Cowen Initiates Coverage On Geron With Buy Rating, Announces Price Target of $10
TD Cowen analyst Tara Bancroft initiates coverage on Geron with a Buy rating and announces Price Target of $10.
No Data